NAAA: N-Acylethanolamine Acid Amidase
A key enzyme in the degradation of bioactive lipid mediators, including the endocannabinoid anandamide.
Gene Information Card
| Symbol | NAAA |
|---|---|
| Full Name | N-Acylethanolamine Acid Amidase |
| Gene Type | Protein coding |
| Chromosomal Location | 4q21.1 |
| NCBI Gene ID | 27163 ncbi.nlm.nih.gov/gene/27163 |
| Ensembl ID | ENSG00000138744 |
| UniProt ID | Q02083 |
| OMIM ID | 607469 |
| HGNC ID | 17936 |
| Aliases | ASAHI, NAAA, ASAH2L, N-acylethanolamine amidohydrolase |
Description
NAAA encodes N-acylethanolamine acid amidase, a lysosomal enzyme that hydrolyzes N-acylethanolamines, including the endocannabinoid anandamide (N-arachidonoylethanolamine), into ethanolamine and free fatty acids. It plays a role in lipid signaling, inflammation, and energy homeostasis.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Inflammatory disorders | NAAA degrades anti-inflammatory N-acylethanolamines; reduced activity may promote inflammation. | PMID: 20628016 |
| Cancer (e.g., prostate, breast) | Altered NAAA expression affects lipid signaling and tumor growth. | PMID: 23563491 |
| Obesity and metabolic syndrome | NAAA modulates energy balance via endocannabinoid system. | PMID: 26925055 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Liver | 12.3 | Medium |
| Kidney | 8.7 | Medium |
| Brain | 5.1 | Low |
| Lung | 4.8 | Low |
| Spleen | 3.2 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HepG2 | 10.5 | Hepatocellular carcinoma cell line |
| HEK293 | 6.2 | Embryonic kidney cells |
| MCF7 | 4.1 | Breast cancer cell line |
| A549 | 3.8 | Lung carcinoma cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.584C>T (p.Thr195Met) | Missense | 0.001% (gnomAD) | Reduced enzymatic activity |
| c.1012G>A (p.Gly338Ser) | Missense | 0.002% (gnomAD) | Unknown functional effect |
| c.1246_1248del (p.Phe416del) | In-frame deletion | Rare | Loss of function |
Mutation functional classification
Loss of Function (LOF)
p.Thr195Met and p.Phe416del reduce or abolish NAAA activity, impairing lipid hydrolysis.
Gain of Function (GOF)
No gain-of-function mutations reported.
Dominant Negative (DN)
Not described.
View complete mutation data：
Gene Ontology (GO)
| • N-acylethanolamine amidohydrolase activity | • lysosome |
| • lipid catabolic process | • endocannabinoid signaling pathway |
Pathways
• Endocannabinoid signaling (Reactome: R-HSA-373753)
• Sphingolipid metabolism (KEGG: hsa00600)
Protein Summary
NAAA is a 359-amino acid lysosomal enzyme with a catalytic N-terminal nucleophile hydrolase domain. It preferentially hydrolyzes N-acylethanolamines at acidic pH, regulating endocannabinoid tone and inflammatory responses. The protein is expressed in liver, kidney, and brain, and its dysregulation is linked to inflammation, cancer, and metabolic disorders.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| NAAA Knockout HEK293 Cell Line | EDJ-KQ8703 | Human | 27163 | Details Get a Quote |
| NAAA Knockout HCT 116 Cell Line | EDJ-KQ34927 | Human | 27163 | Details Get a Quote |
| NAAA Knockout HeLa Cell Line | EDJ-KQ34928 | Human | 27163 | Details Get a Quote |
| NAAA Knockout A-549 Cell Line | EDJ-KQ33654 | Human | 27163 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
